Patients & Caregivers / Closed to Recruitment

text size: Default style Switch styles (larger text) Switch styles (largest text)
Closed to Recruitment

3M Study - Maximizing Medication Management

Description: This study will examine the effect of a new program for teaching family caregivers about managing and administering medications to persons with cognitive impairment.
Study Requirements: family/informal caregiver caring for a friend or family member who needs help managing their medications or a participant who has difficulty remembering and needs help managing medications and has at least one health condition that requires medication management.
Study Length: approximately 6 months
Contact: MaryAnn Oakley at 412-692-2721 or

Perceptual Memory Study

Description: The goal of this research study is to learn more about the neural bases of perceptual decision making, and in doing so, to better understand how memory is affected in aging. Using functional magnetic resonance imaging (fMRI), this study will examine changes in brain function while participants perform cognitive tests. The fMRI scan and test results will help researchers gain insight into which parts of the nervous system are involved in different aspects of the tests.
Study Requirements: Individuals 65 - 85 years of age who are currently experiencing progressive cognitive deficits (Mild Cognitive Impairment) -OR- individuals who are cognitively healthy.
Study Length: One visit (3 - 4 hours)
Contact: closed to recruitment

The Learning and Memory Study

Description: This purpose of this study is to help researchers find out more about how people learn and store information in their memory. The data gathered through this project is expected to add to the knowledge of learning and memory. Participants in this study will undergo a number of evaluations assessing things like language, memory, awareness and day-to-day behaviors.
Study Requirements: 45+ years of age; cognitively healthy individuals or individuals who have a diagnosis of early Alzheimer's disease.
Study Length: One visit (2 - 3 hours)
Contact: closed to recruitment

PeRBA Study

Description: The purpose of this study is to learn how individuals with cognitive impairment and their family members feel about participating in research.
Study Length: 1 interview approximately 45 min. to 1 hr.
Study Requirements: Diagnosis of Mild Cognitive Impairment, AD or other dementia
Contact: closed to recruitment

Alzheimer Disease NeuroImaging Study - Grand Opportunity (ADNI-GO)

Description: The purpose of this study is to determine whether imaging of the brain (through MRI, PET and amyloid imaging scans) can help predict and monitor the onset and progression of Alzheimer's disease. In addition to neuroimaging, the study will collect and test blood and cerebral spinal fluid to determine if biomarkers can predict and monitor the disease.
Study Length: 2 years
Study Requirements:
  • Between 55 and 90 years of age
  • Study partner to accompany to all clinical visits
  • Memory complaint by participant and/or study partner
Contact: closed to recruitment

RI: Rage Inhibitor Study

Description: Many proteins surround the amyloid plaques in Alzheimer's disease patients. One of the proteins, Receptor for Advanced Glycation Endpoints, called RAGE for short, binds to amyloid and may promote inflammation and lead to nerve cell damage. Researchers found that by inhibiting the RAGE protein, plaque formation could be reduced in animal models.
Study Phase: Phase 2
Study Length: 18 months
Study Requirements:
  • Age 50 or older
  • Diagnosis of probable Alzheimer's disease
  • Have a caregiver or family member who can accompany the participant to each study visit
  • Are currently taking AD medication (Aricept, Exelon, or Razadyne)
  • Do not have Type 1 or Type 2 diabetes
Contact: closed to recruitment


Description: ELND005 is being investigated as an orally administered treatment for Alzheimer's disease (AD). ELND005 may prevent or inhibit the build up of amyloid protein in the brains of Alzheimer's disease patients.
Study Length: 18 months
Study Requirements:
  • 50 -85 years of age
  • Diagnosis of Probable AD
  • Have a reliable stud partner
Contact: closed to recruitment

REFLECT – 3 Study

Description: Previous research has shown that rosiglitazone, a diabetes drug, in a new extended release formulation, may have benefit in Alzheimer's patients and that this benefit may be related to a patient's genetic makeup. This study will test the efficacy and safety of the new extended release formulation of rosiglitazone when added to standard approved drug treatment with Acetylcholinesterase Inhibitors (AChEI).
Study Length: Approximately 1 year
Study Requirements: 50 -90 years of age, Diagnosis of Probable AD, Not currently taking Namenda, Have a reliable study partner
Contact: closed to recruitment

Alzheimer Disease Neuroimaging Study (ADNI)

This study will determine whether imaging of the brain (through MRI and PET scans) every 6 months can help predict the onset and monitor the progression of AD. Participants will undergo repeated brain MRI's, cognitive testing, and have blood and urine analysis for biomarkers. PET scans and lumbar punctures are study options.
Study Length: 24-36 months
Study Requirements: 77-90 years of age, Diagnosis of Mild Cognitive Impairment (MCI), Diagnosis of Early AD, Fluent in English,Have a reliable study partner.
Compensation: Participants will receive $100 per visit and an additional $200 for the optional lumbar puncture.
Contact: closed to recruitment

DHA - Omega-3 Fatty Acid

Description: This study will determine whether DHA, an Omega-3 fatty acid, supplementation can slow the progression of cognitive and functional decline over an 18 month period in patients with mild to moderate AD. A subgroup will have MRIs and 2 lumbar punctures with consent.
Study Length: 18 months
Study Requirements: 50 years of age or older, Diagnosis of Probable AD, Have a reliable study partner
Compensation: Participants will receive $200 for undergoing the optional lumbar puncture.
Contact: closed to recruitment


The AMEND (Astrocyte Modulator Evaluation of Neurodegenerative Disease) Study evaluates the safety and effectiveness of an investigational medication that may have a beneficial effect on astrocytes, the cells in the brain that support nerve cell function. People with Alzheimer's disease who meet the following criteria would be eligible:
Study Requirements: between 50 and 90 years of age, have a responsible caregiver (spouse, family member, friend, etc. who is able to attend all clinic visits and answer questions about the volunteer), are either not taking any medication for Alzheimer's disease or are taking a stable dose (90 days) of Aricept or Exelon (FDA approved medications for Alzheimer's disease), are not taking Namenda or Reminyl (other FDA-approved medications for Alzheimer's disease) .
Study Coordinator: Beth Sarles
Contact: closed to recruitment

MPC-7869 Efficacy Study in Patients with Alzheimer's

Some early research studies have shown that people who take anti-inflammatory drugs (such as aspirin or ibuprofen) may have a lower chance of developing Alzheimer’s disease. One of these anti-inflammatory drugs is called flurbiprofen. This drug is approved for use by the FDA. An ingredient of flurbiprofen, called MPC-7869, has been chosen to be studied as a possible treatment for Alzheimer’s disease. People with Alzheimer's disease who meet the following criteria might be eligible:
Study Requirements: Age 55+ and community dwelling, Have a study Partner (caregiver) with whom they have contact at least 4 days a week, Speak English.
Study Coordinator: Donna Simpson
Contact: closed to recruitment

Huperzine A Study

Huperzine A is a natural product extracted from a Chinese herb. It is used in China to treat Alzheimer's disease, and it is available over the counter in the U.S. as an herbal supplement. This study will test whether Huperzine A can help the symptoms of Alzheimer's disease. The Huperzine A used in this study is high quality without other substances in the supplement. Volunteers must:
Study Requirements: have mild to moderate Alzheimer's disease, be age 55 or older, speak English, not currently take a medication for Alzheimer's disease (such as the FDA-approved drugs Aricept, Exelon or Reminyl), have a study partner-a friend or relative who can accompany the volunteer to all clinic visits and answer questions about him/her.
Study Coordinator: Thomas Baumgartner
Contact: closed to recruitment

AAB-001-201 in Patients with Mild to Moderate Alzheimer¹s Disease

The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate AD. AAB-001 is an antibody which binds to and clears beta amyloid peptides. It is designed to provide antibodies to beta amyloid directly to the patient, rather than requiring the patient to mount his/her own individual response. It is believed that this approach may eliminate the need for the patient to mount an immune response to beta amyloid. Animal studies have shown that this approach is equally effective in clearing beta amyloid from the brain as traditional active immunization methods. Participation in this study is approximately 2 years.
Contact: closed to recruitment